Login to Your Account

Optimer's Deficid Gets Expected FDA Nod in C. Diff. Indication

By Jennifer Boggs

Tuesday, May 31, 2011
Executives of Optimer Pharmaceuticals Inc. didn't have to wait until after the long weekend for an FDA decision on the company's macrolide antibiotic Dificid (fidaxomicin). Though the PDUFA date was set for May 30, the agency approved the drug Friday afternoon for treating Clostridium difficile-associated diarrhea (CDAD), a common hospital-acquired infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription